Ibrutinib in Central Nervous System Lymphoma (P8-6.014)
To evaluate the safety and efficacy of ibrutinib in the treatment of Primary central nervous system lymphoma (CNSL). With overall response (OR), complete response (CR), partial response (PR), progression-free survival (PFS), overall survival (OS), and adverse events in scope.
Authors
- Abdulqadir J. J. Nashwan (ORCID: https://orcid.org/0000-0003-4845-4119)
- Mohammad T. Abuawwad (ORCID: https://orcid.org/0000-0002-2703-0942)
- Jaber H. Jaradat (ORCID: https://orcid.org/0000-0002-6488-4664)
- Yousef Al-Bojoq
- Monther N Ramadan
Institutions
- Cairo University (EG)
- Mutah University (JO)
- Hamad Medical Corporation (QA)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211279
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00